Predict your next investment

HEALTHCARE | Biotechnology
matrixgenetics.com

See what CB Insights has to offer

Stage

Unattributed | Alive

Total Raised

$1.6M

Last Raised

$1.6M | 6 yrs ago

About Matrix Genetics

Matrix Genetics is a biotechnology company focused on producing high value products from algae. The company is applying its molecular biology and genetic engineering expertise to cyanobacteria (blue-green algae) since 2007. Matrix Genetics' state-of-the-art, synthetic biology platform is the most cost-efficient method to create customized organisms with a range of traits to meet the needs of multi-billion dollar markets in the fuel, food and feed industries.

Matrix Genetics Headquarter Location

1600 Fairview Avenue E Suite 300

Seattle, Washington, 98102,

United States

206-258-8999

Latest Matrix Genetics News

Matrix Genetics & Proterro Partner on First Commercial Production of Modified Cyanobacteria for Nutrition Market

Feb 10, 2016

Partnership Will Enable Proterro to Develop Supply Chain of Sustainable Algae-Based Products for Health and Nutrition Market, Showcasing the Potential for Larger Scale Production of Spirulina SEATTLE, WA--(Marketwired - Feb 10, 2016) -  Matrix Genetics a biotechnology company focused on producing safe and sustainable products derived from cyanobacteria (a blue-green algae), and Proterro, a biotechnology company with a unique photobioreactor technology to convert waste CO2 into valuable products, announced a partnership to jointly produce high-value nutritional products in Spirulina. Matrix will develop the Spirulina strains and Proterro will grow these strains on their proprietary production system. Matrix was the first company to offer rapid and efficient genetic methods for modifying Spirulina, which unlocks this organism's high protein content, rich availability of B vitamins, minerals and anti-oxidant carotenoids such as beta-carotene. This breakthrough enables Matrix to develop strains with a specific set of traits for a specific set of desired results, as well as the ability to mass produce them. "We're able to precisely and stably introduce new genes into the Spirulina genome, enabling us to purpose-build strains that meet the needs of our partners," said Margaret McCormick, CEO of Matrix Genetics. "Proterro is the first company to leverage this capability and is taking a great step towards fully realizing the promise of Spirulina as a commercial-grade source for years to come. " Proterro will grow Matrix's Spirulina with Proterro's photobioreactor system. Proterro's technology converts the carbon in waste CO2 into valuable products, including industrial biochemicals, food grade and specialty sugars, as well as nutritional products including organic acids, amino acids, nutrients and vitamins. "This partnership leverages the expertise and core competencies of both companies," said Colin South, CEO, at Proterro. "With Matrix's Spirulina plugged into our production system, Proterro will be able to meet the needs of our customers for a sustainable, high-yield source of ingredients for their products. " About Matrix Genetics Matrix Genetics, located in Seattle, Wash. is a biotechnology company focused on producing valuable products derived from cyanobacteria (blue-green algae). The company's state-of-the-art, metabolic engineering and systems biology platform is the most cost-efficient method to customize organisms with a range of traits for multiple industries. More information is available at www.matrixgenetics.com . About Proterro Proterro is a biotechnology company that converts waste CO2 into valuable products under license agreements with its partners. Its technology utilizes photosynthetic organisms in a patented, fully integrated reactor system to produce cost-competitive products for partners in the global food, feed, and energy industries. More information is available at www.proterro.com . Source: Marketwired - All

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Matrix Genetics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Matrix Genetics is included in 3 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

235 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.

B

Biopharmaceuticals

5,732 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

R

Renewable Energy

2,737 items

Includes companies working on technology to support renewable energy generation.

Matrix Genetics Patents

Matrix Genetics has filed 13 patents.

The 3 most popular patent topics include:

  • Cyanobacteria
  • Cytokines
  • Metabolism
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/7/2016

9/29/2020

Photosynthesis, Photochemistry, Metabolism, Cytokines, Cyanobacteria

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

7/7/2016

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

9/29/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Photosynthesis, Photochemistry, Metabolism, Cytokines, Cyanobacteria

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.